Literature DB >> 3196166

Mutations in the hemagglutinin gene associated with influenza virus resistance to norakin.

S Prösch1, H Heider, C Schroeder, D H Krüger.   

Abstract

The nucleotide sequences of the hemagglutinin genes of four norakin-resistant mutants of Influenza A/FPV/Weybridge were determined and compared to the wild-type hemagglutinin. All mutants show one or two amino acid substitutions which are discussed to destabilise the pH 7 conformation of hemagglutinin.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3196166     DOI： 10.1007/bf01315569

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  16 in total

1.  The anticholinergic anti-Parkinson drug Norakin selectively inhibits influenza virus replication.

Authors:  C Schroeder; H Heider; B Hegenscheid; M Schöffel; V I Bubovich; H A Rosenthal
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

2.  Transcription of the influenza virus genome.

Authors:  A J Hay; B Lomniczi; A R Bellamy; J J Skehel
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

3.  [Comparative analysis of primary structure of M-genes in remantadine-resistant and remantadine-sensitive strains of influenza virus A/FPV/Weybridge (H7N7) strains].

Authors:  V A Karginov; V M Blinov; P F Safronov; L V Mamaev; S Ia Golovin
Journal:  Bioorg Khim       Date:  1987-12

4.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors:  R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

5.  Analyses of the antigenicity of influenza haemagglutinin at the pH optimum for virus-mediated membrane fusion.

Authors:  R S Daniels; A R Douglas; J J Skehel; D C Wiley
Journal:  J Gen Virol       Date:  1983-08       Impact factor: 3.891

6.  Antiviral activity of Norakin (triperiden) and related anticholinergic antiparkinsonism drugs.

Authors:  H W Presber; C Schroeder; B Hegenscheid; H Heider; J Reefschläger; H A Rosenthal
Journal:  Acta Virol       Date:  1984-11       Impact factor: 1.162

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  The influence of Norakin on the reproduction of influenza A and B viruses.

Authors:  H Heider; S Markushin; C Schroeder; Y Ghendon
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

9.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

10.  Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling.

Authors:  A Gonzalez-Noriega; J H Grubb; V Talkad; W S Sly
Journal:  J Cell Biol       Date:  1980-06       Impact factor: 10.539
View more
  5 in total

1.  Human hybridomas derived from CD5+ B lymphocytes of patients with chronic lymphocytic leukemia (B-CLL) produce multi-specific natural IgM (kappa) antibodies.

Authors:  S Jahn; J Schwab; A Hansen; H Heider; C Schroeder; A Lukowsky; M Achtman; H Matthes; S T Kiessig; H D Volk
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

2.  Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin.

Authors:  S J Plotch; B O'Hara; J Morin; O Palant; J LaRocque; J D Bloom; S A Lang; M J DiGrandi; M Bradley; R Nilakantan; Y Gluzman
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

3.  Relation between drug resistance and antigenicity among norakin-resistant mutants of influenza A (fowl plague) virus.

Authors:  A I Klimov; S G Markushin; S Prösch; V P Ginzburg; H Heider; A M Heider; C Schröeder; R G Webster
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 4.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 5.  Influenza virus entry.

Authors:  Ming Luo
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.